In light of this science, our firm has been investigating and filing lawsuits on behalf of Byetta, Januvia,
Victoza and other “Incretin-based therapy” users who developed
pancreatitis or pancreatic cancer. As of this month, there are two venues: One a single “judicially coordinated” proceeding involving multiple
pancreatic cancer lawsuits in California state court (administered by
Judge William Highberger in Los Angeles), and two,a federal “multidistrict litigation” proceeding (typically called an
“MDL”) in front of federal Judge Anthony Battaglia in the Southern
District of California.
Diabetes medications work by affecting the GLP-1 therapy. As such, there is a claimed risk of pancreatic cancer.Here's the drug list:
Exenatide
1. Byetta (April 28, 2005) (Amylin / Ely Lilly)
2. Bydureon (January 27, 2012) (Amylin / Eli Lilly)
Liraglutide
Victoza (January 25, 2010) (Novo Nordisk)
Sitagliptin
Januvia (October 16, 2006) (Merck)
Janumet (March 30, 2007) (Merck)
Janumet XR (February 2, 2012) (Merck)
Juvisync (October 7, 2011) (Merck)
Saxagliptin
Onglyza (July 31, 2009) (Bristol Myers Squibb)
Kombiglyze XR (November 5, 2010) (Bristol Myers Squibb)
Alogliptin
Nesina (January 25, 2013) (Takeda)
Kazano (January 25, 2013) (Takeda)
Oseni (January 25, 2013) (Takeda)
Linagliptin
Tradjenta (May 2, 2011) (Boehringer Ingelheim)
Jentadueto (January 30, 2012) (Boehringer Ingelheim)
Pancreatic cancer is a malignant neoplasm originating from transformed cells arising in tissues forming the pancreas. The most common type of pancreatic cancer, accounting for 95% of these tumors, is adenocarcinoma (tumors exhibiting glandular architecture on light microscopy) arising within the exocrine component of the pancreas. A minority arise from islet cells, and are classified as neuroendocrine tumors.
The signs and symptoms that eventually lead to the diagnosis depend on
the location, the size, and the tissue type of the tumor, and may
include abdominal pain, lower back pain, and jaundice (if the tumor compresses the bile duct).
